<DOC>
	<DOCNO>NCT00793793</DOCNO>
	<brief_summary>This study investigate safety , antiviral activity , pharmacokinetics BI 201335 NA HCV genotype 1 infected patient treat 14 day monotherapy follow BI 201335 NA combination therapy PegIFN/RBV additional 14 day treatment-naïve patient ; 28 day BI 201335 NA combination therapy PegIFN/RBV treatment-experienced patient . A secondary objective investigate antiviral activity , potential drug-drug interaction safety combination therapy BI 201335 NA PegIFN/RBV 28 day treatment-naïve patient .</brief_summary>
	<brief_title>Safety , Antiviral Activity PK MRD BI 201335 Chronic Hepatitis C Patients Both Treatment Naive -Experienced</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion criterion : 1a . For treatmentnaïve patient : prior therapy interferon , peginterferon , ribavirin acute chronic hepatitis C infection 1b . For treatmentexperienced patient : confirm virological failure combination treatment approve dose alfa2a alfa2b peginterferon combine ribavirin ; patient must receive least 12 week therapy 90 day washout period prior screening must documentation medical history prior enrolment 1220.2 2 . Age 18 year old 3 . Signed informed consent form prior trial participation 4 . Male female document hysterectomy menopausal female last menstrual period least 6 month prior screen 5 . Chronic hepatitis C infection genotype 1 , diagnose positive HCV serology test ( HCV Ab positive ) detectable HCV RNA least 6 month prior screen 6 . HCV viral load &gt; = 100,000 IU/mL screen 7 . TSH T4 within normal limit adequately control thyroid function 8 . Histological evidence within 36 month prior study enrolment degree chronic necroinflammatory activity presence fibrosis ( Ishak Grade 14 Metavir Grade 13 ) Exclusion criterion : 1 . Patients previously treat least one dose protease inhibitor acute chronic hepatitis C infection 2 . Evidence liver disease due cause chronic HCV infection 3 . Positive ELISA HIV1 HIV2 4 . Hepatitis B virus ( HBV ) infection base presence Hbs Ag HBV DNA 5 . Any previous liver biopsy consistent cirrhosis 6 . Decompensated liver disease evidence ascites , portal hypertension , jaundice hepatic encephalopathy 7 . Haemophilia 8 . Hemoglobinopathy ( e.g. , thalassemia major sickle cell anemia ) 9 . Severe preexist psychiatric disease 10 . Poorly control diabetes mellitus 11 . Ischaemic heart disease 12 . Chronic obstructive airway disease 13 . Autoimmune disease ; include autoimmune hepatitis 14 . History alcohol abuse within past 12 month 15 . Hyperbilirubinemia ( conjugate bilirubin ) &gt; 1.5x ULN 16 . Alkaline phosphatase &gt; 1.5x ULN 17 . ALT AST level &gt; = 5 x ULN 18 . Hemoglobin &lt; 12.0 g/dL woman &lt; 13.0 g/dL men 19 . White blood cell count &lt; 2000 cells/mm3 20 . Absolute Neutrophil Count &lt; 1500 cells/mm3 21 . Platelet count &lt; 100,000 cells/mm3 22 . Prothrombin time INR ( Institutional Normalized Ratio ) prolong &gt; 1.5 x ULN 23 . Usage investigational drug within 30 day prior enrolment ; plan usage investigational drug course current study 24 . Known hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>